

LEADING A NEW ERA

in rapid, on-the-spot sample testing

MBio Diagnostics[®] will be the portable platform of choice for leading providers and users of rapid clinical and analytical testing. Over \$35M has been invested in the development of MBio's technology platform through combined grant and private funding.



MBIO'S PORTABLE DIAGNOSTICS SYSTEMS CONSIST OF SIMPLE, ROBUST READERS AND DISPOSABLE TEST CARTRIDGES THAT DELIVER MULTIPLE RESULTS FROM EVERY SAMPLE.

Medical: Rapid testing to distinguish bacterial from viral disease requires quantitative testing of multiple host-response markers

Veterinary: A panel of wellness tests can be integrated into a single device, run in the vet clinic for prompt action

Environmental: Detection of cyanotoxins generated by harmful algal blooms

Food: Providing prompt and inexpensive testing for more than 30 antibiotics regulated in milk supply

Military: Sepsis and non-infectious shock require rapid, multiplex testing

MBIO'S PROVEN LIGHTDECK[®] TECHNOLOGY DELIVERS AN UNPRECEDENTED COMBINATION OF BENEFITS



Multiplexing:

Cartridges can be configured to run dozens of parallel assays from a single sample



Speed and Ease of Use:

Many assays can be completed in minutes in a simple "load-and-go" workflow

Sensitivity:

Delivering the sensitivity of multi-step laboratory protocols (e.g., ELISA)



Quantitation:

Device output is a quantitative digital measure of each signal

Built-In Quality Control:

MBio cartridges incorporate multiple parallel controls that assure quality of every test result



Low-Cost:

Designed with manufacturing in mind, MBio's disposable cartridges are competitive in all markets

LIGHTDECK® TECHNOLOGY

At the core of all MBio systems is our patented LightDeck® technology, a powerful fluorescence assay illumination and imaging approach. LightDeck® is a unique implementation of planar waveguide technology. While waveguides have been proven by the scientific community for years to be an excellent approach for uniquely sensitive assays, they have not seen widespread uptake in commercial products due to issues of reproducibility and cost. MBio's scientists and engineers have created key, patent-protected advances that solve reproducibility and cost challenges.

The strength of the platform has been proven in multiple implementations all around the world. Recent human clinical research examples include serology assays in the context of tuberculosis disease in Peru and Vietnam, water and food safety testing studies in Ireland and the UK, and a collaboration on malaria testing with the US Army in Kenya.

I.P. SUMMARY

MBio has invested heavily in patent protection of its detection system. The company holds 8 issued US utility patents and 5 design patents on its core technology, as well as 7 issued international patents in China, Japan, South Africa, and several European countries. MBio has an additional 11 patent applications in prosecution worldwide.

PLATFORM LICENSING MODEL

MBio is executing on its strategy of technology partnerships and licensing, while ramping up manufacturing capacity to enable commercialization efforts of our partners.

We work with our partners to develop dedicated assays for the required markers, and customize instruments to give the desired user experience. This allows us to serve our customers on two levels: we meet the end-user desire for fast, simple, and comprehensive testing on-the-spot and we enable our partners to deliver unique products with high performance and low cost of manufacturing.



MBio is a privately held company based in Boulder, Colorado, USA

Leadership

CHRISTOPHER J. MYATT, PH.D.
Chief Executive Officer

MICHAEL J. LOCHHEAD, PH.D.
Executive Vice President and Chief
Technology Officer

Board of Directors

CHRISTOPHER J. MYATT, PH.D.
Chief Executive Officer and Director

MILTON CHANG, PH.D.
Director

ROBERT J. SILVERMAN
Director

Collaborators

DR. ROBERT SCHOOLEY
Head of UCSD Infectious Disease

DR. CONSTANCE BENSON
Head UCSD Antiviral Research Center

DR. CHRIS ELLIOTT
Director Institute for Food Security,
Queen's University Belfast

DR. HECTOR WONG
Director of Critical Care Medicine,
Cincinnati Children's Hospital

Business Advisors

ANDY DRENICK
Board Observer / Advisor

NICK TRAGGIS
I.P. Licensing

Contact:

5603 Arapahoe Avenue, Suite 1
Boulder, CO 80303, USA
Phone (303) 952-2905

info@mbiodx.com
www.mbiodx.com